Regulatory hurdles sits at the center of this dementia and brain health question.

Europe is significantly slower in approving Alzheimer’s disease-modifying therapies than the United States and other major markets, creating a regulatory gap that delays patient access by years. Lecanemab, the first disease-modifying Alzheimer’s treatment to gain European approval, arrived in April 2025—nearly two years after its US authorization in 2023. This two-year approval lag reflects the European Medicines Agency’s more cautious regulatory approach, which prioritizes comprehensive safety assessment over rapid market entry.

The EMA’s stringent standards were on full display when it rejected donanemab in March 2025, citing safety concerns about brain swelling and microhemorrhages that appeared in clinical trials, even though the same drug had already been approved in the United States. This article examines why Europe’s approval process moves slower, what safety issues are driving regulatory rejections, how this compares to approvals in other countries, and what patients and healthcare systems should expect as more therapies await European decisions. The regulatory hurdles extend beyond individual drug reviews. Even when therapies receive EMA approval, national healthcare systems within EU member states impose additional restrictions based on cost-effectiveness assessments and their own safety risk tolerances, creating a second layer of delay before patients can actually access these treatments.

Why Does Europe’s Alzheimer’s Approval Process Lag Behind the United States?
Brain Swelling and Microhemorrhages—The Safety Concerns Blocking Donanemab Approval
A Global Approval Disparity—What the US and Japan Have Done Differently
From Regulatory Approval to Actual Patient Access—The Second Barrier
The Donanemab Reversal—When Initial Rejection Becomes Conditional Approval
Why the EMA’s Caution May Not Protect Patients the Way Regulators Intend
What’s Next for Europe’s Alzheimer’s Treatment Pipeline?
Conclusion

Why Does Europe’s Alzheimer’s Approval Process Lag Behind the United States?

The European Medicines Agency operates on a fundamentally different timeline and standards framework compared to the US Food and Drug Administration. While the FDA approved lecanemab in January 2023, the EMA’s review process for the same drug stretched over nearly two years, involving multiple evaluation rounds, initial rejections, formal appeals, and a reversal of the initial negative decision. This is not a rare exception but part of a broader pattern: over the past decade, the United States and Japan have approved seven Alzheimer’s therapies, while Europe has approved only one.

The difference stems partly from regulatory philosophy. The EMA tends to require more extensive data packages and longer review periods to achieve what it views as adequate safety documentation. For disease-modifying therapies targeting early-stage Alzheimer’s—where patients still have limited cognitive symptoms—European regulators are particularly cautious about approving drugs with demonstrated side effects when the clinical benefit may not appear for months or years. This conservative stance has prevented faster access to these treatments, leaving European patients waiting while Americans can already fill prescriptions.

Why Does Europe's Alzheimer's Approval Process Lag Behind the United States?

Brain Swelling and Microhemorrhages—The Safety Concerns Blocking Donanemab Approval

The primary reason the EMA rejected donanemab in March 2025 was a safety signal called ARIA—amyloid-related imaging abnormalities. Donanemab triggered brain swelling or microhemorrhages in 25% of Phase 3 trial participants, roughly twice the rate observed with lecanemab. For regulators, particularly in Europe, this elevated risk posed an unacceptable safety profile in patients who may not yet show obvious cognitive decline.

However, if you are a patient with early cognitive changes or a family member considering these therapies, understand that the EMA’s caution reflects a real tradeoff: the drugs may slow disease progression, but they carry documented risks of brain imaging abnormalities that could have long-term consequences. The American and Japanese regulators concluded the benefits outweighed these risks for appropriate patient populations. Europe disagreed—at least initially. After a re-examination request, the CHMP (Committee for Medicinal Products for Human Use) issued a positive opinion on donanemab in July 2025, though the final European Commission decision was still pending at the time this article was written.

A Global Approval Disparity—What the US and Japan Have Done Differently

When you compare regulatory approvals across major markets, the disparity is striking. The United States approved seven Alzheimer’s therapies in the past decade, Japan followed suit with competitive approvals, but Europe managed only one: lecanemab. This gap means European patients are locked out of treatment options that their counterparts in other wealthy nations can access. Why do these differences exist? The FDA has adopted a more expedited framework for serious diseases with unmet medical needs, particularly for drugs showing disease-modifying potential.

The agency balances efficacy and safety differently than the EMA—American regulators emphasize patient choice and the option to pursue a therapy even if risks exist, whereas European regulators view their role as gatekeeping to prevent any therapy reaching patients if risks seem insufficiently managed. Japan has followed patterns closer to the US model. These are not secret decisions; they reflect stated regulatory philosophies. For patients and families, this means treatment options available in New York or Tokyo simply do not exist in Berlin or Paris, at least not yet.

A Global Approval Disparity—What the US and Japan Have Done Differently

From Regulatory Approval to Actual Patient Access—The Second Barrier

Even when the EMA grants approval, the regulatory hurdle is only the first step. National healthcare systems across EU member states conduct their own cost-effectiveness assessments and safety evaluations before deciding whether to cover a drug or restrict its use to specific patient populations. These assessments can delay access by additional months or years.

A drug approved by the EMA may be available in Germany within weeks but restricted to university hospital specialists in Italy or subject to strict prescribing criteria in France. For example, once lecanemab gained EMA approval in April 2025, it still faced evaluations by health technology assessment bodies in each EU country. Some nations fast-tracked reviews; others took months to determine whether the drug’s price—typically tens of thousands of euros per patient annually—justified reimbursement in publicly funded healthcare systems. Patients in countries with restrictive assessments faced the frustration of a therapy being legally approved in Europe but still functionally inaccessible in their own healthcare system without paying out of pocket.

The Donanemab Reversal—When Initial Rejection Becomes Conditional Approval

Donanemab’s pathway illustrates how the EMA’s process can shift under pressure. The CHMP issued a negative opinion in March 2025, recommending against approval based on ARIA safety concerns. Pharmaceutical sponsors and patient advocacy groups appealed, requesting a re-examination. In July 2025, after additional data review and presumably more detailed risk-benefit analysis, the same committee issued a positive opinion, reversing its initial stance.

This reversal might seem like a win for faster access, but it highlights a limitation: the process is unpredictable and opaque to outsiders. There is no clear threshold at which the EMA shifts from “reject” to “approve”—it depends on how compelling the sponsor’s rebuttal appears to committee members and whether new data emerges during the appeal. For patients and doctors, this uncertainty is frustrating. You may plan treatment around an expected approval only to face months of delay, then watch the approval process restart from scratch.

The Donanemab Reversal—When Initial Rejection Becomes Conditional Approval

Why the EMA’s Caution May Not Protect Patients the Way Regulators Intend

The EMA’s conservative approach is rooted in a principle: do no harm to patients by approving drugs with unacceptable risks. However, there is an ironic consequence: by delaying approval, the EMA may be preventing treatment for patients whose disease is rapidly progressing. Alzheimer’s is progressive and irreversible; delay is itself a harm.

A patient who waits two years for European approval may have already lost cognitive abilities that a therapy could have preserved had it been available earlier. For example, a 65-year-old diagnosed with mild cognitive impairment in 2023 might have benefited from lecanemab had it been approved in Europe at that time. Instead, she waited until April 2025 while already experiencing disease progression. By the time lecanemab became available, her disease may have advanced beyond the stage where the clinical benefit—documented in trials of early-stage patients—would apply to her.

What’s Next for Europe’s Alzheimer’s Treatment Pipeline?

The donanemab re-examination pending final European Commission decision in 2025-2026 suggests Europe may gradually expand its Alzheimer’s therapy approvals. As more data emerges from real-world use of lecanemab in the US, and as patient advocacy in Europe grows, regulatory pressure may shift toward faster evaluation of subsequent therapies.

However, no major structural change to the EMA’s review process has been announced. Looking ahead, European patients should expect gradual expansion of Alzheimer’s treatment access over the next 2-3 years, but not parity with the US market. Healthcare systems will likely continue implementing restrictive access criteria based on cost and patient selection, meaning that even approved therapies will not be universally available across Europe.

Conclusion

Europe’s regulatory framework for Alzheimer’s therapies prioritizes comprehensive safety assessment over rapid patient access, resulting in approval timelines 2+ years behind the United States and Japan. While the EMA’s caution may reflect a genuine commitment to safety, it has the practical effect of delaying treatment for patients whose disease cannot wait. The rejection of donanemab in March 2025 and its conditional reversal in July 2025 underscore the EMA’s struggle to balance risk and benefit in an era of disease-modifying therapies.

If you or a family member is living with Alzheimer’s disease or mild cognitive impairment in Europe, the current reality is limited treatment options compared to other high-income countries. Advocacy efforts and real-world safety data from lecanemab’s use in the US may eventually shift Europe’s regulatory stance. In the meantime, understanding these approval gaps, the specific safety concerns driving rejections, and the secondary barriers imposed by national healthcare systems is essential for navigating treatment decisions.